CAPITOLO 6
RIFERIMENTI BIBLIOGRAFICI
Ackley, C.D., J.K. Yamamoto, N. Levy, N.C. Pedersen, and M.D. Cooper. 1990. Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus. J Virol. 64:5652-5.
al Shamkhani, B., Puklavec, Brown, James, Barclay. 1996. OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand. Eur J Immunol. . 26:1695-1699.
Alimonti, J.B., T.B. Ball, and K.R. Fowke. 2003. Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS. J Gen Virol. 84:1649-61.
Allen, T.M., M. Altfeld, X.G. Yu, K.M. O'Sullivan, M. Lichterfeld, S. Le Gall, M. John, B.R. Mothe, P.K. Lee, E.T. Kalife, D.E. Cohen, K.A. Freedberg, D.A. Strick, M.N. Johnston, A. Sette, E.S. Rosenberg, S.A. Mallal, P.J. Goulder, C. Brander, and B.D. Walker. 2004. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol. 78:7069-78. Altman, J.D., P.A. Moss, P.J. Goulder, D.H. Barouch, M.G. McHeyzer-Williams, J.I. Bell, A.J.
McMichael, and M.M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:94-6.
Asemissen, A.M., D. Nagorsen, U. Keilholz, A. Letsch, A. Schmittel, E. Thiel, and C. Scheibenbogen. 2001. Flow cytometric determination of intracellular or secreted IFNgamma for the quantification of antigen reactive T cells. J Immunol Methods. 251:101-8.
Ashkenazi, A., and V.M. Dixit. 1998. Death receptors: signaling and modulation. Science. 281:1305-8.
Ashkenazi, A., and V.M. Dixit. 1999. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol. 11:255-60.
Asjo, B., H. Stavang, B. Sorensen, I. Baksaas, J. Nyhus, and N. Langeland. 2002. Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy. AIDS Res Hum Retroviruses. 18:1357-65.
Auwerx, J., R. Esnouf, E. De Clercq, and J. Balzarini. 2004. Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors. Mol Pharmacol. 65:244-51.
Barlough, J.E., C.D. Ackley, J.W. George, N. Levy, R. Acevedo, P.F. Moore, B.A. Rideout, M.D. Cooper, and N.C. Pedersen. 1991. Acquired immune dysfunction in cats with experimentally induced feline immunodeficiency virus infection: comparison of short-term and long-short-term infections. J Acquir Immune Defic Syndr. 4:219-27.
Bashford, C.L., G. Menestrina, P.A. Henkart, and C.A. Pasternak. 1988. Cell damage by cytolysin. Spontaneous recovery and reversible inhibition by divalent cations. J Immunol. 141:3965-74.
Baxby, D., and E. Paoletti. 1992. Potential use of non-replicating vectors as recombinant vaccines. Vaccine. 10:8-9.
Beatty, J.A., B.J. Willett, E.A. Gault, and O. Jarrett. 1996. A longitudinal study of feline immunodeficiency virus-specific cytotoxic T lymphocytes in experimentally infected cats, using antigen-specific induction. J Virol. 70:6199-206.
Beebe, A.M., N. Dua, T.G. Faith, P.F. Moore, N.C. Pedersen, and S. Dandekar. 1994. Primary stage of feline immunodeficiency virus infection: viral dissemination and cellular targets. J Virol. 68:3080-91.
Bendinelli, M., M. Pistello, S. Lombardi, A. Poli, C. Garzelli, D. Matteucci, L. Ceccherini-Nelli, G. Malvaldi, and F. Tozzini. 1995. Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen. Clin Microbiol Rev. 8:87-112.
Betts, M.R., J.M. Brenchley, D.A. Price, S.C. De Rosa, D.C. Douek, M. Roederer, and R.A. Koup. 2003. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods. 281:65-78.
Bigornia, L., K.M. Lockridge, and E.E. Sparger. 2001. Construction and in vitro characterization of attenuated feline immunodeficiency virus long terminal repeat mutant viruses. J Virol. 75:1054-60.
Birx, D.L., L.D. Loomis-Price, N. Aronson, J. Brundage, C. Davis, L. Deyton, R. Garner, F. Gordin, D. Henry, W. Holloway, T. Kerkering, R. Luskin-Hawk, J. McNeil, N. Michael, P. Foster Pierce, D. Poretz, S. Ratto-Kim, P. Renzullo, N. Ruiz, K. Sitz, G. Smith, C. Tacket, M. Thompson, E. Tramont, B. Yangco, R. Yarrish, and R.R. Redfield. 2000. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators. J Infect Dis. 181:881-9.
Borrow, P., H. Lewicki, B.H. Hahn, G.M. Shaw, and M.B. Oldstone. 1994. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 68:6103-10.
Borsutzky, S., V. Fiorelli, T. Ebensen, A. Tripiciano, F. Rharbaoui, A. Scoglio, C. Link, F. Nappi, M. Morr, S. Butto, A. Cafaro, P.F. Muhlradt, B. Ensoli, and C.A. Guzman. 2003. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. Eur J Immunol. 33:1548-56.
Braley. 1994. FeLV and FIV: survey shows prevalence in the United States and Europe. Feline Practice. 22:25-28.
Brenchley, J.M., T.W. Schacker, L.E. Ruff, D.A. Price, J.H. Taylor, G.J. Beilman, P.L. Nguyen, A. Khoruts, M. Larson, A.T. Haase, and D.C. Douek. 2004. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 200:749-59.
Brown, S.A., J.L. Hurwitz, X. Zhan, P.C. Doherty, and K.S. Slobod. 2005. CD8+ T-cells: are they sufficient to prevent, contain or eradicate HIV-1 infection? Curr Drug Targets Infect Disord. 5:113-9.
Brunner, K.T., J. Mauel, J.C. Cerottini, and B. Chapuis. 1968. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology. 14:181-96.
Cao, H., N. Tamilarasu, and T.M. Rana. 2006. Orientation and affinity of HIV-1 Tat fragments in Tat-TAR complex determined by fluorescence resonance energy transfer. Bioconjug Chem. 17:352-8.
Chahroudi, A., G. Silvestri, and M.B. Feinberg. 2003. Measuring T cell-mediated cytotoxicity using fluorogenic caspase substrates. Methods. 31:120-6.
Chatterji, U., A. de Parseval, and J.H. Elder. 2002. Feline immunodeficiency virus OrfA is distinct from other lentivirus transactivators. J Virol. 76:9624-34.
Chatterji, U., C.K. Grant, and J.H. Elder. 2000. Feline immunodeficiency virus Vif localizes to the nucleus. J Virol. 74:2533-40.
Choi, I.S., R. Hokanson, and E.W. Collisson. 2000. Anti-feline immunodeficiency virus (FIV) soluble factor(s) produced from antigen-stimulated feline CD8(+) T lymphocytes suppresses FIV replication. J Virol. 74:676-83.
Coiras, M., E. Camafeita, T. Urena, J.A. Lopez, F. Caballero, B. Fernandez, M.R. Lopez-Huertas, M. Perez-Olmeda, and J. Alcami. 2006. Modifications in the human T cell proteome induced by intracellular HIV-1 Tat protein expression. Proteomics. 6 Suppl 1:S63-73. Cullen, B.R., and W.C. Greene. 1989. Regulatory pathways governing HIV-1 replication. Cell.
58:423-6.
Currier, J.R., U. Visawapoka, S. Tovanabutra, C.J. Mason, D.L. Birx, F.E. McCutchan, and J.H. Cox. 2006. CTL epitope distribution patterns in the gag and nef proteins of HIV-1 from subtype A infected subjects in Kenya: Use of multiple peptide sets increases the detectable breadth of the CTL response. BMC Immunol. 7:8.
Darlix, J.L., C. Gabus, M.T. Nugeyre, F. Clavel, and F. Barre-Sinoussi. 1990. Cis elements and trans-acting factors involved in the RNA dimerization of the human immunodeficiency virus HIV-1. J Mol Biol. 216:689-99.
De Parseval, A. 2004. Feline immunodeficiency virus targets activated CD4+ T cells by using CD134 as a binding receptor. PNAS. 101:13044-13049.
Dean, G.A., S. Himathongkham, and E.E. Sparger. 1999. Differential cell tropism of feline immunodeficiency virus molecular clones in vivo. J Virol. 73:2596-603.
Doria-Rose, N.A., and N.L. Haigwood. 2003. DNA vaccine strategies: candidates for immune modulation and immunization regimens. Methods. 31:207-16.
Dow, S.W., M.L. Poss, and E.A. Hoover. 1990. Feline immunodeficiency virus: a neurotropic lentivirus. J Acquir Immune Defic Syndr. 3:658-68.
Elder, J.H.a.P.T.R. 1994. Molecular properties of feline immunodeficiency virus (FIV). Infectious agents and disease. 2:361.
Elyar, J.S., M.C. Tellier, J.M. Soos, and J.K. Yamamoto. 1997. Perspectives on FIV vaccine development. Vaccine. 15:1437-44.
Essajee, S.M., R. Yogev, H. Pollack, B. Greenhouse, K. Krasinski, and W. Borkowsky. 2002. Recombinant glycoprotein vaccines for human immunodeficiency virus-infected children and their effects on viral quasispecies. Clin Diagn Lab Immunol. 9:79-82. Ferri, K.F., E. Jacotot, M. Geuskens, and G. Kroemer. 2000. Apoptosis and karyogamy in
syncytia induced by the HIV-1-envelope glycoprotein complex. Cell Death Differ. 7:1137-9.
Flynn, J.N., C.A. Cannon, G. Reid, M.A. Rigby, J.C. Neil, and O. Jarrett. 1995. Induction of feline immunodeficiency virus-specific cell-mediated and humoral immune responses following immunization with a multiple antigenic peptide from the envelope V3 domain. Immunology. 85:171-5.
Flynn, J.N., C.A. Cannon, D. Sloan, J.C. Neil, and O. Jarrett. 1999. Suppression of feline immunodeficiency virus replication in vitro by a soluble factor secreted by CD8+ T lymphocytes. Immunology. 96:220-9.
Furuya, T., Y. Kawaguchi, T. Miyazawa, Y. Fujikawa, Y. Tohya, M. Azetaka, E. Takahashi, and T. Mikami. 1990. Existence of feline immunodeficiency virus infection in Japanese cat population since 1968. Nippon Juigaku Zasshi. 52:891-3.
Gahery-Segard, H., G. Pialoux, B. Charmeteau, S. Sermet, H. Poncelet, M. Raux, A. Tartar, J.P. Levy, H. Gras-Masse, and J.G. Guillet. 2000. Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J Virol. 74:1694-703.
Gallo, R.C. 1999. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine. Proc Natl Acad Sci U S A. 96:8324-6.
Garg, H., F.J. Fuller, and W.A. Tompkins. 2004. Mechanism of feline immunodeficiency virus envelope glycoprotein-mediated fusion. Virology. 321:274-86.
Gemeniano, M.C., E.T. Sawai, C.M. Leutenegger, and E.E. Sparger. 2003. Feline immunodeficiency virus ORF-Ais required for virus particle formation and virus infectivity. J Virol. 77:8819-30.
Gemeniano, M.C., E.T. Sawai, and E.E. Sparger. 2004. Feline immunodeficiency virus Orf-A localizes to the nucleus and induces cell cycle arrest. Virology. 325:167-74.
George, J.W., N.C. Pedersen, and J. Higgins. 1993. The effect of age on the course of experimental feline immunodeficiency virus infection in cats. AIDS Res Hum Retroviruses. 9:897-905.
Giannecchini, S., D. Del Mauro, D. Matteucci, and M. Bendinelli. 2001. AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: reevaluation of neutralizing antibody levels elicited by a protective and a nonprotective vaccine after removal of antisubstrate cell antibodies. J Virol. 75:4424-9.
Gloster, S.E., P. Newton, D. Cornforth, J.D. Lifson, I. Williams, G.M. Shaw, and P. Borrow. 2004. Association of strong virus-specific CD4 T cell responses with efficient natural control of primary HIV-1 infection. Aids. 18:749-55.
Godoy-Ramirez, K., K. Franck, and H. Gaines. 2000. A novel method for the simultaneous assessment of natural killer cell conjugate formation and cytotoxicity at the single-cell level by multi-parameter flow cytometry. J Immunol Methods. 239:35-44.
Godoy-Ramirez, K., B. Makitalo, R. Thorstensson, E. Sandstrom, G. Biberfeld, and H. Gaines. 2005. A novel assay for assessment of HIV-specific cytotoxicity by multiparameter flow cytometry. Cytometry A. 68:71-80.
Goepfert, P.A., A. Bansal, B.H. Edwards, G.D. Ritter, Jr., I. Tellez, S.A. McPherson, S. Sabbaj, and M.J. Mulligan. 2000. A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon. J Virol. 74:10249-55.
Goldberg, J.E., S.W. Sherwood, and C. Clayberger. 1999. A novel method for measuring CTL and NK cell-mediated cytotoxicity using annexin V and two-color flow cytometry. J Immunol Methods. 224:1-9.
Gonin, P., A. Fournier, W. Oualikene, A. Moraillon, and M. Eloit. 1995. Immunization trial of cats with a replication-defective adenovirus type 5 expressing the ENV gene of feline immunodeficiency virus. Vet Microbiol. 45:393-401.
Gougeon, M.L., H. Lecoeur, A. Dulioust, M.G. Enouf, M. Crouvoiser, C. Goujard, T. Debord, and L. Montagnier. 1996. Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol. 156:3509-20.
Greenough, T.C., M. Somasundaran, D.B. Brettler, R.M. Hesselton, A. Alimenti, F. Kirchhoff, D. Panicali, and J.L. Sullivan. 1994. Normal immune function and inability to isolate virus in culture in an individual with long-term human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses. 10:395-403.
Guadalupe, M., E. Reay, S. Sankaran, T. Prindiville, J. Flamm, A. McNeil, and S. Dandekar. 2003. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol. 77:11708-17.
Guiot, A.L., D. Rigal, and G. Chappuis. 1997. Spontaneous programmed cell death (PCD) process of lymphocytes of FIV-infected cats: cellular targets and modulation. Vet Immunol Immunopathol. 58:93-106.
Gurunathan, S., D.M. Klinman, and R.A. Seder. 2000. DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol. 18:927-74.
Haddad, D., J. Ramprakash, M. Sedegah, Y. Charoenvit, R. Baumgartner, S. Kumar, S.L. Hoffman, and W.R. Weiss. 2000. Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J Immunol. 165:3772-81.
Hameed, A., K.J. Olsen, M.K. Lee, M.G. Lichtenheld, and E.R. Podack. 1989. Cytolysis by Ca-permeable transmembrane channels. Pore formation causes extensive DNA degradation and cell lysis. J Exp Med. 169:765-77.
Harbour. 1992. Feline immunodeficiency virus infection as a model for HIV infection in man. Rev. Med. Virol.
. 2:43-49.
Harrer, T., E. Harrer, S.A. Kalams, P. Barbosa, A. Trocha, R.P. Johnson, T. Elbeik, M.B. Feinberg, S.P. Buchbinder, and B.D. Walker. 1996. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol. 156:2616-23.
Hartmann, K. 1998. Feline immunodeficiency virus infection: an overview. Vet J. 155:123-37. Heibein, J.A., I.S. Goping, M. Barry, M.J. Pinkoski, G.C. Shore, D.R. Green, and R.C. Bleackley.
2000. Granzyme B-mediated cytochrome c release is regulated by the Bcl-2 family members bid and Bax. J Exp Med. 192:1391-402.
Hel, Z., J. Nacsa, E. Tryniszewska, W.P. Tsai, R.W. Parks, D.C. Montefiori, B.K. Felber, J. Tartaglia, G.N. Pavlakis, and G. Franchini. 2002. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. J Immunol. 169:4778-87.
Henkart, P.A., P.J. Millard, C.W. Reynolds, and M.P. Henkart. 1984. Cytolytic activity of purified cytoplasmic granules from cytotoxic rat large granular lymphocyte tumors. J Exp Med. 160:75-93.
Herr, W., U. Protzer, A.W. Lohse, G. Gerken, K.H. Meyer zum Buschenfelde, and T. Wolfel. 1998. Quantification of CD8+ T lymphocytes responsive to human immunodeficiency virus (HIV) peptide antigens in HIV-infected patients and seronegative persons at high risk for recent HIV exposure. J Infect Dis. 178:260-5.
Hohdatsu, T., M. Okubo, and H. Koyama. 1998. Feline CD8+ T cell non-cytolytic anti-feline immunodeficiency virus activity mediated by a soluble factor(s). J Gen Virol. 79 ( Pt 11):2729-35.
Jarrett, O., A.M. Pacitti, M.J. Hosie, and G. Reid. 1991. Comparison of diagnostic methods for feline leukemia virus and feline immunodeficiency virus. J Am Vet Med Assoc. 199:1362-4.
Jeng, C.R., R.V. English, T. Childers, M.B. Tompkins, and W.A. Tompkins. 1996. Evidence for CD8+ antiviral activity in cats infected with feline immunodeficiency virus. J Virol. 70:2474-80.
Jerome, K.R., D.D. Sloan, and M. Aubert. 2003. Measurement of CTL-induced cytotoxicity: the caspase 3 assay. Apoptosis. 8:563-71.
Jewell, N.A., and L.M. Mansky. 2000. In the beginning: genome recognition, RNA encapsidation and the initiation of complex retrovirus assembly. J Gen Virol. 81:1889-99.
Jordan, H.L., J. Howard, W.A. Tompkins, and S. Kennedy-Stoskopf. 1995. Detection of feline immunodeficiency virus in semen from seropositive domestic cats (Felis catus). J Virol. 69:7328-33.
Kahn, J.O., D.W. Cherng, K. Mayer, H. Murray, and S. Lagakos. 2000. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial. Jama. 284:2193-202.
Kam, C.M., D. Hudig, and J.C. Powers. 2000. Granzymes (lymphocyte serine proteases): characterization with natural and synthetic substrates and inhibitors. Biochim Biophys Acta. 1477:307-23.
Kelleher, A.D., and S.L. Rowland-Jones. 2000. Functions of tetramer-stained HIV-specific CD4(+) and CD8(+) T cells. Curr Opin Immunol. 12:370-4.
Kennedy, M.K., M. Glaccum, S.N. Brown, E.A. Butz, J.L. Viney, M. Embers, N. Matsuki, K. Charrier, L. Sedger, C.R. Willis, K. Brasel, P.J. Morrissey, K. Stocking, J.C. Schuh, S. Joyce, and J.J. Peschon. 2000. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med. 191:771-80.
Kittiworakarn, J., A. Lecoq, G. Moine, R. Thai, E. Lajeunesse, P. Drevet, C. Vidaud, A. Menez, and M. Leonetti. 2006. HIV-1 Tat raises an adjuvant-free humoral immune response controlled by its core region and its ability to form cysteine-mediated oligomers. J Biol Chem. 281:3105-15.
Koup, R.A., J.T. Safrit, Y. Cao, C.A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D.D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 68:4650-5. Kran, A.M., B. Sorensen, J. Nyhus, M.A. Sommerfelt, I. Baksaas, J.N. Bruun, and D. Kvale.
2004. HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x). Aids. 18:1875-83.
Kuate, S., C. Stahl-Hennig, H. Stoiber, G. Nchinda, A. Floto, M. Franz, U. Sauermann, S. Bredl, L. Deml, R. Ignatius, S. Norley, P. Racz, K. Tenner-Racz, R.M. Steinman, R. Wagner, and K. Uberla. 2006. Immunogenicity and efficacy of immunodeficiency virus-like particles pseudotyped with the G protein of vesicular stomatitis virus. Virology.
Kundu-Raychaudhuri, S., A. Sevin, P. Kilgo, M. Nokta, R.B. Pollard, and T.C. Merigan. 2001. Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946). AIDS Res Hum Retroviruses. 17:1371-8.
Lecoeur, H., M. Fevrier, S. Garcia, Y. Riviere, and M.L. Gougeon. 2001. A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. J Immunol Methods. 253:177-87.
Leslie, A.J., K.J. Pfafferott, P. Chetty, R. Draenert, M.M. Addo, M. Feeney, Y. Tang, E.C. Holmes, T. Allen, J.G. Prado, M. Altfeld, C. Brander, C. Dixon, D. Ramduth, P. Jeena, S.A. Thomas, A. St John, T.A. Roach, B. Kupfer, G. Luzzi, A. Edwards, G. Taylor, H. Lyall, G. Tudor-Williams, V. Novelli, J. Martinez-Picado, P. Kiepiela, B.D. Walker, and P.J. Goulder. 2004. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med. 10:282-9.
Letsch, A., and C. Scheibenbogen. 2003. Quantification and characterization of specific T-cells by antigen-specific cytokine production using ELISPOT assay or intracellular cytokine staining. Methods. 31:143-9.
Levine, A.M., S. Groshen, J. Allen, K.M. Munson, D.J. Carlo, A.E. Daigle, F. Ferre, F.C. Jensen, S.P. Richieri, R.J. Trauger, J.W. Parker, P.L. Salk, and J. Salk. 1996. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1
Immunogen: long-term follow-up. J Acquir Immune Defic Syndr Hum Retrovirol. 11:351-64.
Levy, J.K., H.M. Scott, J.L. Lachtara, and P.C. Crawford. 2006. Seroprevalence of feline leukemia virus and feline immunodeficiency virus infection among cats in North America and risk factors for seropositivity. J Am Vet Med Assoc. 228:371-6.
Levy, Y., H. Gahery-Segard, C. Durier, A.S. Lascaux, C. Goujard, V. Meiffredy, C. Rouzioux, R.E. Habib, M. Beumont-Mauviel, J.G. Guillet, J.F. Delfraissy, and J.P. Aboulker. 2005. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. Aids. 19:279-86.
Lin, Y.C., Z. Beck, G.M. Morris, A.J. Olson, and J.H. Elder. 2003. Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases. J Virol. 77:6589-600.
Liu, L., A. Chahroudi, G. Silvestri, M.E. Wernett, W.J. Kaiser, J.T. Safrit, A. Komoriya, J.D. Altman, B.Z. Packard, and M.B. Feinberg. 2002. Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat Med. 8:185-9.
Lombardi, S., C. Garzelli, C. La Rosa, L. Zaccaro, S. Specter, G. Malvaldi, F. Tozzini, F. Esposito, and M. Bendinelli. 1993. Identification of a linear neutralization site within the third variable region of the feline immunodeficiency virus envelope. J Virol. 67:4742-9. Lombardi, S., C. Garzelli, M. Pistello, C. Massi, D. Matteucci, F. Baldinotti, G. Cammarota, L. da
Prato, P. Bandecchi, F. Tozzini, and et al. 1994. A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity. J Virol. 68:8374-9.
Lutz, H., E. Isenbugel, R. Lehmann, R.H. Sabapara, and C. Wolfensberger. 1992. Retrovirus infections in non-domestic felids: serological studies and attempts to isolate a lentivirus. Vet Immunol Immunopathol. 35:215-24.
Mackewicz, C.E., H.W. Ortega, and J.A. Levy. 1991. CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest. 87:1462-6.
Manrique, M.L., S.A. Gonzalez, and J.L. Affranchino. 2004. Functional relationship between the matrix proteins of feline and simian immunodeficiency viruses. Virology. 329:157-67. Marechal, V., M.C. Prevost, C. Petit, E. Perret, J.M. Heard, and O. Schwartz. 2001. Human
immunodeficiency virus type 1 entry into macrophages mediated by macropinocytosis. J Virol. 75:11166-77.
Markosyan, R.M., F.S. Cohen, and G.B. Melikyan. 2003. HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation. Mol Biol Cell. 14:926-38.
Markovic, I. 2006. Advances in HIV-1 entry inhibitors: strategies to interfere with receptor and coreceptor engagement. Curr Pharm Des. 12:1105-19.
Matsui, M., O. Moriya, and T. Akatsuka. 2003. Enhanced induction of hepatitis C virus-specific cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmid. Vaccine. 21:1629-39.
Matteucci, D., M. Pistello, P. Mazzetti, S. Giannecchini, D. Del Mauro, L. Zaccaro, P. Bandecchi, F. Tozzini, and M. Bendinelli. 1996. Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies. J Virol. 70:617-22.
Matzinger, P. 1991. The JAM test. A simple assay for DNA fragmentation and cell death. J Immunol Methods. 145:185-92.
McKay, P.F., D.H. Barouch, J.E. Schmitz, R.S. Veazey, D.A. Gorgone, M.A. Lifton, K.C. Williams, and N.L. Letvin. 2003. Global dysfunction of CD4 T-lymphocyte cytokine expression in
simian-human immunodeficiency virus/SIV-infected monkeys is prevented by vaccination. J Virol. 77:4695-702.
McShane, H., R. Brookes, S.C. Gilbert, and A.V. Hill. 2001. Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun. 69:681-6.
McShane, H., and A. Hill. 2005. Prime-boost immunisation strategies for tuberculosis. Microbes Infect. 7:962-7.
Millard, P.J., M.P. Henkart, C.W. Reynolds, and P.A. Henkart. 1984. Purification and properties of cytoplasmic granules from cytotoxic rat LGL tumors. J Immunol. 132:3197-204. Miller, D.L., S.K. Taylor, D.S. Rotstein, M.B. Pough, M.C. Barr, C.A. Baldwin, M. Cunningham,
M. Roelke, and D. Ingram. 2006. Feline Immunodeficiency Virus and Puma Lentivirus in Florida panthers (Puma concolor coryi): Epidemiology and Diagnostic Issues. Vet Res Commun. 30:307-17.
Mooij, P., and J.L. Heeney. 2001. Rational development of prophylactic HIV vaccines based on structural and regulatory proteins. Vaccine. 20:304-21.
Motokawa, K., T. Hohdatsu, A. Imori, S. Arai, and H. Koyama. 2005. Mutations in feline immunodeficiency (FIV) virus envelope gene V3-V5 regions in FIV-infected cats. Vet Microbiol. 106:33-40.
Musey, L., J. Hughes, T. Schacker, T. Shea, L. Corey, and M.J. McElrath. 1997. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med. 337:1267-74.
Mustafa, F., P. Jayanth, P.S. Phillip, A. Ghazawi, R.D. Schmidt, K.A. Lew, and T.A. Rizvi. 2005. Relative activity of the feline immunodeficiency virus promoter in feline and primate cell lines. Microbes Infect. 7:233-9.
Natoli, E., A. Baggio, and D. Pontier. 2001. Male and female agonistic and affiliative relationships in a social group of farm cats (Felis catus L.). Behav Processes. 53:137-143.
Norimine, J., T. Miyazawa, Y. Kawaguchi, K. Tomonaga, Y.S. Shin, T. Toyosaki, M. Kohmoto, M. Niikura, Y. Tohya, and T. Mikami. 1993. Feline CD4 molecules expressed on feline non-lymphoid cell lines are not enough for productive infection of highly lymphotropic feline immunodeficiency virus isolates. Arch Virol. 130:171-8.
North, T.W., R.C. Cronn, K.M. Remington, R.T. Tandberg, and R.C. Judd. 1990. Characterization of reverse transcriptase from feline immunodeficiency virus. J Biol Chem. 265:5121-8.
Ogg, G.S., and A.J. McMichael. 1998. HLA-peptide tetrameric complexes. Curr Opin Immunol. 10:393-6.
Olmsted, R.A., V.M. Hirsch, R.H. Purcell, and P.R. Johnson. 1989. Nucleotide sequence analysis of feline immunodeficiency virus: genome organization and relationship to other lentiviruses. Proc Natl Acad Sci U S A. 86:8088-92.
Omori, M., R. Pu, T. Tanabe, W. Hou, J.K. Coleman, M. Arai, and J.K. Yamamoto. 2004. Cellular immune responses to feline immunodeficiency virus (FIV) induced by dual-subtype FIV vaccine. Vaccine. 23:386-98.
Operario, D.J., H.M. Reynolds, and B. Kim. 2005. Comparison of DNA polymerase activities between recombinant feline immunodeficiency and leukemia virus reverse transcriptases. Virology. 335:106-21.
Paillart, J.C., and H.G. Gottlinger. 1999. Opposing effects of human immunodeficiency virus type 1 matrix mutations support a myristyl switch model of gag membrane targeting. J Virol. 73:2604-12.
Pancino, G., I. Fossati, C. Chappey, S. Castelot, B. Hurtrel, A. Moraillon, D. Klatzmann, and P. Sonigo. 1993. Structure and variations of feline immunodeficiency virus envelope glycoproteins. Virology. 192:659-62.
Paroli, M., A. Propato, D. Accapezzato, V. Francavilla, E. Schiaffella, and V. Barnaba. 2001. The immunology of HIV-infected long-term non-progressors--a current view. Immunol Lett. 79:127-9.
Paterson, D.J., W.A. Jefferies, J.R. Green, M.R. Brandon, P. Corthesy, M. Puklavec, and A.F. Williams. 1987. Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol Immunol. 24:1281-90.
Patrick, M.K., J.B. Johnston, and C. Power. 2002. Lentiviral neuropathogenesis: comparative neuroinvasion, neurotropism, neurovirulence, and host neurosusceptibility. J Virol. 76:7923-31.
Payne, S.L., and J.H. Elder. 2001. The role of retroviral dUTPases in replication and virulence. Curr Protein Pept Sci. 2:381-8.
Pedersen, N.C., E.W. Ho, M.L. Brown, and J.K. Yamamoto. 1987. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science. 235:790-3. Perkus, M.E., J. Tartaglia, and E. Paoletti. 1995. Poxvirus-based vaccine candidates for cancer,
AIDS, and other infectious diseases. J Leukoc Biol. 58:1-13.
Petrovas, C., Y.M. Mueller, and P.D. Katsikis. 2004. HIV-specific CD8+ T cells: serial killers condemned to die? Curr HIV Res. 2:153-62.
Phillips, T.R., C. Lamont, D.A. Konings, B.L. Shacklett, C.A. Hamson, P.A. Luciw, and J.H. Elder. 1992. Identification of the Rev transactivation and Rev-responsive elements of feline immunodeficiency virus. J Virol. 66:5464-71.
Piriou, L., S. Chilmonczyk, N. Genetet, and E. Albina. 2000. Design of a flow cytometric assay for the determination of natural killer and cytotoxic T-lymphocyte activity in human and in different animal species. Cytometry. 41:289-97.
Pistello, M., M. Moscardini, P. Mazzetti, F. Bonci, L. Zaccaro, P. Isola, G. Freer, S. Specter, D. Matteucci, and M. Bendinelli. 2002. Development of feline immunodeficiency virus ORF-A (tat) mutants: in vitro and in vivo characterization. Virology. 298:84-95.
Podack, E.R., and G. Dennert. 1983. Assembly of two types of tubules with putative cytolytic function by cloned natural killer cells. Nature. 302:442-5.
Pu, R., J. Coleman, M. Omori, M. Arai, T. Hohdatsu, C. Huang, T. Tanabe, and J.K. Yamamoto. 2001. Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates. Aids. 15:1225-37.
Puls, R.L., and S. Emery. 2006. Therapeutic vaccination against HIV: current progress and future possibilities. Clin Sci (Lond). 110:59-71.
Ray, N., and R.W. Doms. 2006. HIV-1 coreceptors and their inhibitors. Curr Top Microbiol Immunol. 303:97-120.
Reche, P.A., D.B. Keskin, R.E. Hussey, P. Ancuta, D. Gabduza, and E.L. Reinherz. 2006. Elicitation from virus-naive individuals of cytotoxic T lymphocytes directed against conserved HIV-1 epitopes. Med Immunol. 5:1.
Rimmelzwaan, G.F., K.H. Siebelink, H. Broos, G.A. Drost, K. Weijer, R. van Herwijnen, and A.D. Osterhaus. 1994. gag- and env-specific serum antibodies in cats after natural and experimental infection with feline immunodeficiency virus. Vet Microbiol. 39:153-65. Robinson, B., J. Turchan, C. Anderson, A. Chauhan, and A. Nath. 2006. Modulation of human
immunodeficiency virus infection by anticonvulsant drugs. J Neurovirol. 12:1-4.
Rowland-Jones, S.L., D.F. Nixon, M.C. Aldhous, F. Gotch, K. Ariyoshi, N. Hallam, J.S. Kroll, K. Froebel, and A. McMichael. 1993. specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet. 341:860-1.
Saenz, D.T., N. Loewen, M. Peretz, T. Whitwam, R. Barraza, K.G. Howell, J.M. Holmes, M. Good, and E.M. Poeschla. 2004. Unintegrated lentivirus DNA persistence and accessibility to expression in nondividing cells: analysis with class I integrase mutants. J Virol. 78:2906-20.
Sasaki, S., R.R. Amara, A.E. Oran, J.M. Smith, and H.L. Robinson. 2001. Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases. Nat Biotechnol. 19:543-7.
Schmittel, A., U. Keilholz, E. Thiel, and C. Scheibenbogen. 2000. Quantification of tumor-specific T lymphocytes with the ELISPOT assay. J Immunother. 23:289-95.
Schmitz, J.E., M.J. Kuroda, S. Santra, V.G. Sasseville, M.A. Simon, M.A. Lifton, P. Racz, K. Tenner-Racz, M. Dalesandro, B.J. Scallon, J. Ghrayeb, M.A. Forman, D.C. Montefiori, E.P. Rieber, N.L. Letvin, and K.A. Reimann. 1999. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 283:857-60.
Seth, A., Y. Yasutomi, H. Jacoby, J.C. Callery, S.M. Kaminsky, W.C. Koff, D.F. Nixon, and N.L. Letvin. 2000. Evaluation of a lipopeptide immunogen as a therapeutic in HIV type 1-seropositive individuals. AIDS Res Hum Retroviruses. 16:337-43.
Shi, L., S. Mai, S. Israels, K. Browne, J.A. Trapani, and A.H. Greenberg. 1997. Granzyme B (GraB) autonomously crosses the cell membrane and perforin initiates apoptosis and GraB nuclear localization. J Exp Med. 185:855-66.
Shi, Y. 2002. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell. 9:459-70.
Shimojima, M., T. Miyazawa, Y. Ikeda, E.L. McMonagle, H. Haining, H. Akashi, Y. Takeuchi, M.J. Hosie, and B.J. Willett. 2004. Use of CD134 as a primary receptor by the feline immunodeficiency virus. Science. 303:1192-5.
Song, W., E.W. Collisson, P.M. Billingsley, and W.C. Brown. 1992. Induction of feline immunodeficiency virus-specific cytolytic T-cell responses from experimentally infected cats. J Virol. 66:5409-17.
Sullivan, N.J., T.W. Geisbert, J.B. Geisbert, L. Xu, Z.Y. Yang, M. Roederer, R.A. Koup, P.B. Jahrling, and G.J. Nabel. 2003. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature. 424:681-4.
Suni, M.A., L.J. Picker, and V.C. Maino. 1998. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. J Immunol Methods. 212:89-98.
Sutton, V.R., M.E. Wowk, M. Cancilla, and J.A. Trapani. 2003. Caspase activation by granzyme B is indirect, and caspase autoprocessing requires the release of proapoptotic mitochondrial factors. Immunity. 18:319-29.
Takeda, A., H. Igarashi, H. Nakamura, M. Kano, A. Iida, T. Hirata, M. Hasegawa, Y. Nagai, and T. Matano. 2003. Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model. J Virol. 77:9710-5.
Tellier, M.C., R. Pu, D. Pollock, A. Vitsky, J. Tartaglia, E. Paoletti, and J.K. Yamamoto. 1998. Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats. Aids. 12:11-8.
Tomonaga, K., and T. Mikami. 1996. Molecular biology of the feline immunodeficiency virus auxiliary genes. J Gen Virol. 77 ( Pt 8):1611-21.
Tompkins, M.B., M.E. Bull, J.L. Dow, J.M. Ball, E.W. Collisson, B.J. Winslow, A.P. Phadke, T.W. Vahlenkamp, and W.A. Tompkins. 2002. Feline immunodeficiency virus infection is characterized by B7+CTLA4+ T cell apoptosis. J Infect Dis. 185:1077-93.
Ueland, K., and H. Lutz. 1992. Prevalence of feline leukemia virus and antibodies to feline immunodeficiency virus in cats in Norway. Zentralbl Veterinarmed B. 39:53-8.
Valdez, H., N.L. Carlson, A.B. Post, R. Asaad, P.S. Heeger, M.M. Lederman, P.V. Lehmann, and D.D. Anthony. 2002. HIV long-term non-progressors maintain brisk CD8 T cell responses to other viral antigens. Aids. 16:1113-8.
Verrier, B. 2005. Therapeutic vaccination for chronic infectious diseases: lessons from HIV-1. J Clin Virol. 34 Suppl 1:S9-S12.
Verschoor, E.J., M.J. Willemse, J.G. Stam, A.L. van Vliet, H. Pouwels, S.K. Chalmers, M.C. Horzinek, P.J. Sondermeijer, W. Hesselink, and A. de Ronde. 1996. Evaluation of subunit vaccines against feline immunodeficiency virus infection. Vaccine. 14:285-9. Vitale, M., L.M. Neri, S. Comani, E. Falcieri, R. Rizzoli, R. Rana, and S. Papa. 1989. Natural killer
function in flow cytometry. II. Evaluation of NK lytic activity by means of target cell morphological changes detected by right angle light scatter. J Immunol Methods. 121:115-20.
Walker, B.D., and E.S. Rosenberg. 2000. Containing HIV after infection. Nat Med. 6:1094-5. Warren, T.L., and G.J. Weiner. 2000. Uses of granulocyte-macrophage colony-stimulating
factor in vaccine development. Curr Opin Hematol. 7:168-73.
Watanabe, N., S.C. De Rosa, A. Cmelak, R. Hoppe, L.A. Herzenberg, and M. Roederer. 1997. Long-term depletion of naive T cells in patients treated for Hodgkin's disease. Blood. 90:3662-72.
Waters, A.K., A.P. De Parseval, D.L. Lerner, J.C. Neil, F.J. Thompson, and J.H. Elder. 1996. Influence of ORF2 on host cell tropism of feline immunodeficiency virus. Virology. 215:10-6.
Willett, B.J., C.A. Cannon, and M.J. Hosie. 2003. Expression of CXCR4 on feline peripheral blood mononuclear cells: effect of feline immunodeficiency virus infection. J Virol. 77:709-12.
Willett, B.J., J.N. Flynn, and M.J. Hosie. 1997. FIV infection of the domestic cat: an animal model for AIDS. Immunol Today. 18:182-9.
Willett, B.J., E.L. McMonagle, S. Ridha, and M.J. Hosie. 2006. Differential utilization of CD134 as a functional receptor by diverse strains of feline immunodeficiency virus. J Virol. 80:3386-94.
Woodland, D.L. 2004. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol. 25:98-104.
Yamamoto, J.K., T. Hohdatsu, R.A. Olmsted, R. Pu, H. Louie, H.A. Zochlinski, V. Acevedo, H.M. Johnson, G.A. Soulds, and M.B. Gardner. 1993. Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus. J Virol. 67:601-5.
Yamamoto, J.K., T. Okuda, C.D. Ackley, H. Louie, E. Pembroke, H. Zochlinski, R.J. Munn, and M.B. Gardner. 1991. Experimental vaccine protection against feline immunodeficiency virus. AIDS Res Hum Retroviruses. 7:911-22.
Yamamoto, J.K., E. Sparger, E.W. Ho, P.R. Andersen, T.P. O'Connor, C.P. Mandell, L. Lowenstine, R. Munn, and N.C. Pedersen. 1988. Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats. Am J Vet Res. 49:1246-58. Zarei, S., S. Abraham, J.F. Arrighi, O. Haller, T. Calzascia, P.R. Walker, T.M. Kundig, C. Hauser,
and V. Piguet. 2004. Lentiviral transduction of dendritic cells confers protective antiviral immunity in vivo. J Virol. 78:7843-5.
